Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT06284122
Title Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 (MorningLyte)
Acronym MorningLyte
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors The Lymphoma Academic Research Organisation
Age Groups: adult | senior
Covered Countries FRA | ESP | DEU | BEL

No variant requirements are available.